Alnylam Pharmaceuticals, Inc. (ALNY)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+28.66% vs
Rating Accuracy
50.0% (1 of 2*)
FV Performance
FV Accuracy
8 Hits (160.0% Hit Rate)
FV Avg. Distance
-1.75%
FV Accuracy
8 Hits (114.29% Hit Rate)
FV Avg. Distance
-1.75%
FV Accuracy
8 Hits (42.11% Hit Rate)
FV Avg. Distance
-1.75%
FV Accuracy
11 Hits (25.58% Hit Rate)
FV Avg. Distance
+23.58%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
John M. Maraganore
Employees
1,323
Industry
Endocrinology and Metabolism Biopharmaceuticals
Sector
Healthcare
Headquarters
Cambridge
Exchange
NASDAQ
Website
http://www.alnylam.comSummary Stats
Market Cap
28.8B
Revenue
961M
Net Income
-1.18B
EPS
-$9.78
Price-to-Earnings
-23.97
Price-to-Book
-426.36
Debt-to-Equity
-53.27
News
Analyst Ratings
Price targets projected by 23 analysts
High
$225.00
Average
$163.61
Low
$93.00
Ratings calculated by 24 analysts
Buy
16
Hold
8
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q3 2022
Above by $0.20
-$1.58 +11.2%
-1.78
-1.51
Down 4%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--